CEMI(Delisted)
Chembio Diagnostics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CEMI
Chembio Diagnostics, Inc.
A leading point-of-care diagnostics company focused on infectious diseases
3661 Horseblock Road, Medford, NY 11763
--
Chembio Diagnostics, Inc., was incorporated in Nevada in December 1985. The company develops, manufactures, sells and licenses rapid care diagnostic tests (POCTs) that detect infectious diseases. The company's main products currently on the market are four rapid tests for HIV antibodies, two rapid tests for syphilis and a rapid test for canine leishmaniasis. On May 5, 2004, the company completed the merger with Trading Solutions. Through this merger, Chembio Diagnostics became its wholly-owned subsidiary. It is through this merger that the management and business of Chembio Diagnostics became the management and business of Trading Solutions. As part of the deal, the company changed its name to Chembio Diagnostics. In 2003, the company had sold its former business, so before the merger, the company had no specific business.
Company Financials
EPS
CEMI has released its 2022 Q4 earnings. EPS was reported at -0.01, versus the expected 0, missing expectations. The chart below visualizes how CEMI has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
